<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098761</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000396779</org_study_id>
    <secondary_id>PBTC-017</secondary_id>
    <secondary_id>VION-VNP40101M</secondary_id>
    <nct_id>NCT00098761</nct_id>
  </id_info>
  <brief_title>VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors</brief_title>
  <official_title>Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of VNP40101M in&#xD;
      treating young patients with recurrent, progressive, or refractory primary brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of VNP40101M in&#xD;
           pediatric patients with recurrent, progressive, or refractory primary brain tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug and its active metabolite VNP4090CE in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      receiving ≥ 1 of the following prior therapies: craniospinal irradiation (yes vs no),&#xD;
      autologous bone marrow transplant (yes vs no), and &gt; 2 myelosuppressive chemotherapy or&#xD;
      myelosuppressive biologic therapy regimens (yes vs no).&#xD;
&#xD;
      Patients receive VNP40101M IV over 30 minutes on days 1-5. Treatment repeats every 42 days&#xD;
      for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 2-6 patients per stratum receive escalating doses of VNP40101M until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose at which 25% of patients&#xD;
      experience dose-limiting toxicity. A total of 12 patients are treated at the MTD.&#xD;
&#xD;
      Patients are followed for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4-60 patients (2-30 per stratum) will be accrued for this study&#xD;
      within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the maximum tolerated dose</measure>
    <time_frame>First 6 weeks of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>First 6 weeks of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Day 1 of therapy</time_frame>
    <description>Plasma samples for pharmacokinetic studies will be collected with the first dose of the study drug pre-infusion, and 5, 15, and 30 minutes, 1 hour, 2 hours, and 4 hours after the end of infusion. VNP40101M plasma concentration-time data will be modeled and the individual pharmacokinetic pararmeters volume of the central compartment, elimination rate constant, and half-life will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response to VNP40101M</measure>
    <time_frame>Prior to course 3, 5, and 7 and end of therapy</time_frame>
    <description>MRI of the brain will be obtained prior to couses 3, 5, and 7 and at the end of therapy</description>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laromustine</intervention_name>
    <description>This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.</description>
    <other_name>Cloretazine</other_name>
    <other_name>VNP40101M</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed* primary brain tumor, including benign brain tumors (e.g.,&#xD;
             low-grade glioma)&#xD;
&#xD;
               -  Recurrent or progressive disease OR refractory to standard therapy NOTE:&#xD;
                  *Patients with intrinsic brain stem or diffuse optic pathway tumors do not&#xD;
                  require histological confirmation, but must have clinical and/or radiographic&#xD;
                  evidence of disease progression&#xD;
&#xD;
          -  No bone marrow disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  21 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% (for patients &gt; 16 years of age) OR&#xD;
&#xD;
          -  Lansky 50-100% (for patients ≤ 16 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL* NOTE: *Unsupported&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  No overt hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  BUN &lt; 25 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN for age OR&#xD;
&#xD;
          -  Glomerular filtration rate &gt; 70 mL/min&#xD;
&#xD;
          -  No overt renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Shortening fraction ≥ 30% by echocardiogram OR&#xD;
&#xD;
          -  Ejection fraction ≥ 50% by gated radionucleotide study&#xD;
&#xD;
          -  No clinically significant cardiac arrhythmia by EKG&#xD;
&#xD;
          -  No overt cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 60% of predicted&#xD;
&#xD;
          -  Chest X-ray normal (defined as absence of pulmonary infiltrates, pneumonitis, pleural&#xD;
             effusion, pulmonary hemorrhage, or fibrosis) AND a resting pulse oximetry reading of &gt;&#xD;
             94% in room air (for patients who cannot perform the DLCO)&#xD;
&#xD;
          -  No overt pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Neurologic deficits allowed provided there has been no deficit progression for ≥ 1&#xD;
             week before study entry&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known hypersensitivity to polyethylene glycol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 6 months since prior allogeneic bone marrow or stem cell transplantation&#xD;
&#xD;
          -  At least 3 months since prior autologous bone marrow or stem cell transplantation&#xD;
&#xD;
          -  More than 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], or epoetin alfa)&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive anticancer biologic therapy&#xD;
&#xD;
          -  No concurrent routine colony-stimulating factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for&#xD;
             nitrosoureas or mitomycin) and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided dose is stable or decreasing for ≥ 1 week&#xD;
             before study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior craniospinal irradiation ≥ 18 Gy&#xD;
&#xD;
          -  At least 2 weeks since prior focal irradiation to the primary tumor and/or symptomatic&#xD;
             metastatic sites&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 7 days since prior nonmyelosuppressive anticancer therapy&#xD;
&#xD;
          -  At least 7 days since prior investigational agents&#xD;
&#xD;
          -  Concurrent enzyme-inducing anticonvulsant drugs allowed&#xD;
&#xD;
          -  No other concurrent anticancer or experimental agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sri Gururangan, MRCP (UK)</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15;14(4):1124-30. doi: 10.1158/1078-0432.CCR-07-4242.</citation>
    <PMID>18281546</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett/PBTC Operations and Biostatistics Center Executive Director</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

